Literature DB >> 24998573

Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells.

Yi-Wu Dang1, Jing Zeng, Rong-Quan He, Min-Hua Rong, Dian-Zhong Luo, Gang Chen.   

Abstract

BACKGROUND: miR-152 is involved in the genesis and development of several malignancies. However, its role in HCC has not been fully clarified. The aim of this study was to investigate the clinicopathological significance of miR-152 and its effect on the malignant phenotype of HCC cells.
METHODS: miR-152 expression was detected using real-time quantitative RT-PCR in 89 pairs of HCC formalin-fixed paraffin-embedded and their adjacent tissues. Functionally, in vitro effects and mechanisms of action of miR-152 on proliferation, viability, caspase activity, apoptosis and motility were explored in HepG2, HepB3 and SNU449 cells, as assessed by spectrophotometry, fluorimetry, fluorescence microscopy, wound-healing and Western blotting, respectively.
RESULTS: miR-152 expression in HCC was downregulated remarkably compared to that in adjacent hepatic tissues. miR-152 levels in groups of advanced clinical stage, larger tumor size and positive HBV infection, were significantly lower than in other groups. A miR-152 mimic could suppress cell growth, inhibit cell motility and increase caspase activity and apoptosis in HCC cell lines. Furthermore, Western blotting showed that the miR-152 mimic downregulated Wnt-1, DNMT1, ERK1/2, AKT and TNFRS6B signaling. Intriguingly, inverse correlation of TNFRF6B and miR-152 expression was found in HCC and bioinformatics confirmed that TNFRF6B might be a target of miR- 152.
CONCLUSIONS: Underexpression of miR-152 plays a vital role in hepatocarcinogenesis and lack of miR-152 is related to the progression of HCC through deregulation of cell proliferation, motility and apoptosis. miR-152 may act as a tumor suppressor miRNA by also targeting TNFRSF6B and is therefore a potential candidate biomarker for HCC diagnosis, prognosis and molecular therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24998573     DOI: 10.7314/apjcp.2014.15.12.4969

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  31 in total

Review 1.  Cell-free microRNAs in blood and other body fluids, as cancer biomarkers.

Authors:  Blanca Ortiz-Quintero
Journal:  Cell Prolif       Date:  2016-06       Impact factor: 6.831

2.  miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.

Authors:  Laura Pazzaglia; Chiara Novello; Amalia Conti; Serena Pollino; Piero Picci; Maria Serena Benassi
Journal:  Cell Oncol (Dordr)       Date:  2016-11-29       Impact factor: 6.730

3.  Clinical implication of long non-coding RNA NEAT1 expression in hepatocellular carcinoma patients.

Authors:  Sien Guo; Wenjie Chen; Yihuan Luo; Fanghui Ren; Tengfei Zhong; Minhua Rong; Yiwu Dang; Zhenbo Feng; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs.

Authors:  D D H Tran; C Kessler; S E Niehus; M Mahnkopf; A Koch; T Tamura
Journal:  Oncogene       Date:  2017-09-04       Impact factor: 9.867

Review 5.  MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma.

Authors:  Sirio Fiorino; Maria Letizia Bacchi-Reggiani; Michela Visani; Giorgia Acquaviva; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Luca Di Tommaso; Arrigo Bondi; Sergio Sabbatani; Andrea Domanico; Carlo Fabbri; Paolo Leandri; Annalisa Pession; Elio Jovine; Dario de Biase
Journal:  World J Gastroenterol       Date:  2016-04-21       Impact factor: 5.742

6.  Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.

Authors:  R Tang; T Zhong; Y Dang; X Zhang; P Li; G Chen
Journal:  Clin Transl Oncol       Date:  2015-08-26       Impact factor: 3.405

7.  MiR-30a-5p suppresses cell growth and enhances apoptosis of hepatocellular carcinoma cells via targeting AEG-1.

Authors:  Rongquan He; Lihua Yang; Xiaomiao Lin; Xin Chen; Xinggu Lin; Fanglin Wei; Xiaona Liang; Yihuan Luo; Yuzhuang Wu; Tingqing Gan; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

8.  Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma.

Authors:  Feng Wang; Houqun Ying; Bangshun He; Yuqin Pan; Huiling Sun; Shukui Wang
Journal:  Tumour Biol       Date:  2015-11-03

9.  The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients.

Authors:  Rady E El-Araby; Mahmoud A Khalifa; Mona M Zoheiry; Manal Y Zahran; Mohamed I Rady; Raafat A Ibrahim; Mohamed D El-Talkawy; Faiza M Essawy
Journal:  Cancer Gene Ther       Date:  2019-07-18       Impact factor: 5.854

Review 10.  HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Authors:  Devis Pascut; Minh Hoang; Nhu N Q Nguyen; Muhammad Yogi Pratama; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.